OBJECTIVE: The anti-obesity properties of a new b 3 -adrenergic agonist (Trecadrine) were examined in a diet-induced obesity model, including the effects on OB and uncoupling protein (UCP-1 and -2) gene expression. MEASUREMENTS: Control rats and cafeteria-fed rats were treated with placebo or Trecadrine for 35 days. Leptin and UCP (1 and 2) mRNA levels were determined by reverse transcription ± polymerase chain reaction (RT-PCR) methodology in adipose tissue and gastrocnemius muscle. RESULTS: Animals fed a cafeteria diet increased body weight, fat content, white adipose tissue (WAT), brown adipose tissue (BAT) weights and oxygen consumption in relation to lean controls. A rise in plasma leptin, WAT OB gene expression as well as circulating free fatty acids levels was found in obese rats as compared with lean controls. Trecadrine administration to cafeteria-fed animals decreased fat content, WAT weight, circulating leptin and fatty acids concentrations, and WAT OB gene expression, reaching comparable values to lean controls, while WAT O 2 consumption was increased in these animals. Also, an increase in BAT UCP1 mRNA levels was found through a twoway analysis of variance in control and obese animals after Trecadrine administration. Gastrocnemius muscle UCP2 gene expression was reduced in lean Trecadrine-treated and diet-induced obese animals as compared to controls, while an increase was found in cafeteria-fed animals after Trecadrine administration. A negative correlation between WAT O 2 consumption and UCP2 expression was found in control animals, but not in the cafeteria-fed groups, suggesting a differential response to the b 3 -adrenergic compound in lean and obese animals, which is in agreement with the reported statistical interactions between obesity and Trecadrine administration found for WAT O 2 consumption and muscle UCP2 expression, as well as for plasma leptin and WAT leptin expression. CONCLUSION: The new b 3 -adrenergic agonist, Trecadrine, decreases fat content and increases gastrocnemius muscle UCP2 gene expression in a diet-induced obesity model. This sheds additional light on the action mechanism of compounds with af®nity for b 3 -adrenoceptors and other potential anti-obesity agents.
Introduction
Chronic imbalance between energy intake and expenditure may result in fat deposition and ultimately in the onset of obesity. These processes have been associated with genetic and environmental factors involving excessive energy intake and decreased physical activity, but also with social and economic forces as well as metabolic and endocrine abnormalities. 1, 2 The sympathetic nervous system via b 3 -adrenergic receptors plays a central role in controlling energy expenditure and body composition. 3 Thus, b 3 -adrenoceptor stimulation increases lipolysis in the white adipose tissue (WAT) of several species, including humans, and thermogenesis in brown adipose tissue (BAT) and skeletal muscle. 3, 4 Therefore, a number of selective b 3 -adrenoceptor agonists have been examined for their anti-obesity and anti-diabetic properties in humans and rodents. 5, 6 In this context, new compounds are continuously synthesized in order to be applied to obese patients, as is the case with Trecadrine, a molecule with af®nity for b 3 -adrenoceptors designed to be used in gastrointestinal disorders, 7 which increases energy utilization and leads to adipose tissue mass losses in obese rodents. 8 On the other hand, several studies indicate that the OB gene and its protein product, leptin, are involved in body weight balance 9, 10 and may be affected by b 3 -adrenergic agonists. 11, 12 Furthermore, the uncoupling proteins (UCPs) such as UCP1, UCP2 and UCP3 have been associated with thermogenesis and mitochondrial proton gradient regulation, 13, 14 which raises new possibilities for understanding the mechanism of action of b 3 -adrenoceptor agonists.
In the current study, the aims were to assess the impact of a recently developed b 3 -adrenergic agonist, Trecadrine, 7, 8, 15 on body composition, plasma insulin and leptin as well as on the mRNA expression levels of several genes involved in body weight homeostasis and thermoregulation (OB, UCP1 and UCP2 in WAT, BAT and gastrocnemius muscle, respectively) in lean and obese animals, which were fed a cafeteria diet.
Methods

Drug
Trecadrine, a diphenyl-methylene-ethylamine derivative compound, whose formula and characterization as a b 3 -adrenergic agonist agent have been previously published, 15 was supplied by Wassermann-Chiesi (BarcelonaaMilano).
Experimental design
Thirty-two female Wistar rats weighing about 180 ± 200 g (6 weeks old) were obtained from the Center of Applied Pharmacology (CIFA, Spain). The animals (four per cage) were housed in a temperature controlled room (20 ± 22 C) with a reversed 12 h light, 12 h dark cycle. After an adaptation period of 1 week, the animals were divided into two groups: one group (control, n 16) was fed a pelleted diet (362.0 kcala100 g; Rodent Toxicology Diet, B&K Universal), containing 18% of energy as protein, 76% of energy as carbohydrate and 6% of energy as lipid by dry weight. The second group (obese, n 16) was fed a cafeteria diet (hypercaloric diet, 467.0 kcala100 g). The cafeteria diet was composed of the following items: pate Â, chips, chocolate, bacon, biscuits and pelleted diet in a proportion of 2 : 1 : 1 : 1 : 1 : 1 as published elsewhere. 8 The composition was 9% of energy as protein, 29% of energy as carbohydrate and 62% of energy as lipid by dry weight. 8 The animals had an ad libitum access to water and food.
In order to evaluate the effects of Trecadrine, control animals were divided after 40 days into two new subgroups, (control, n 8; control Trecadrine, n 8). Both groups were kept on a pelleted diet and water ad libitum. Also, after 40 days the cafeteria diet obese animals were divided into two new subgroups to test the effects of Trecadrine, (obese, n 8; obese Trecadrine, n 8). Rats from both the obese Trecadrine and control Trecadrine groups were given Trecadrine (1 mgakgaday) by oral gavage for 35 days, while control and obese groups received vehicle (saline). Obese groups continued to be fed a cafeteria diet and water ad libitum up to day 75. Body weight and food intake were recorded daily. At the end of the experimental period, rats were killed by decapitation and blood samples and several other tissues were collected. All procedures were conducted in accordance with the principles and guidelines established by the University Committee for the care and use of laboratory animals.
Organs weights
After the animals were decapitated, gastrocnemius muscle, interscapular BAT and abdominal WAT were isolated, weighed and frozen. Samples of gastrocnemius muscle, BAT and WAT were also frozen at 780 C for subsequent RNA extraction.
In vitro oxygen consumption
Oxygen consumption from fragmented white adipose tissue was measured with an YSI Model 5300 biological oxygen monitor using a Clark-type oxygen electrode. 15 
Body composition
Body composition was assessed at the end of the experimental period, in anaesthetized animals, by using a non-invasive electromagnetic instrument devised for rodents (EM-SCAN Model SA-2). This system offers adequate accuracy (`3%) and repeatability (`1%), as described elsewhere, 16 and has been validated in our laboratory for normal, obese and diabetic rats.
Biochemical measurements
Serum glucose was analysed using standardized methods with a dry-chemistry procedure (Spotchem, Menarini). Plasma free fatty acid concentration was measured by an enzymatic colourimetric method ACS-ACOD (Wako Chemicals). Plasma insulin was assayed by radioimmunoassay (RIA) using 125 Ilabelled insulin (INSIK-5, 51 kBqavial) with a human insulin standard (Sorin Biomedica). Plasma leptin concentrations were measured by a sandwich enzyme-linked immunosorbent assay (ELISA) employing a rabbit anti-murine leptin IgG and a murine leptin standard. 17 
RNA extraction
Total RNA from 100 mg samples of WAT, BAT and gastrocnemius muscle was isolated using the Ultraspec TM -II (Bioteck) RNA isolation system. 18 Reverse transcription ± polymerase chain reaction (RT-PCR)
The expression of OB, UCP1 and UCP2 mRNA was determined by semi-quantitative reverse-transcription PCR in a thermocycler (GeneAmp PCR system 2400, Perkin-Elmer Cetus). cDNAs were synthesized by reverse transcription from total RNA (0.4 mg) using Moloney murine leukemia virus (MMLV) reverse transcriptase (Gibco BRL), RNase inhibitor (Promega) and random primer p(dN) 6 (Boehringer Mannheim), and incubated for 60 min at 37 C. A control without reverse transcriptase veri®ed that the residual genomic DNA was not ampli®ed. PCR ampli®cation was carried out after reverse transcription product reactions, using selective oligonucleotide primers for H and 314 base pairs for b-actin. The ampli®ed products were resolved in 1.5% agarose gels and PCR bands were semi-quantitated by scanning densitometry using the Gel Doc 1000 UV¯uorescent gel documentation system and molecular analyst software (Bio-Rad). Levels of mRNA were normalized to b-actin mRNA content and expressed as a percentage of control levels. The mRNA levels of OB, UCP1 and UCP2 were normalized to those of b-actin mRNA, because it has been previously demonstrated that bactin mRNA was constantly expressed in obese and control animals with or without Trecadrine treatment in WAT, BAT and gastrocnemius muscle. Validation experiments of PCR assays using known quantities of total RNA (from 0 to 0.8 mg) were performed in WAT, BAT and gastrocnemius muscle for OB, UCP1, UCP2 and b-actin. Thus, 0.2 mg was chosen as a suitable amount of total RNA to avoid the plateau effect ( Figure 1 ). The identity of PCR products was demonstrated after digestion with restriction enzymes, which yielded the predicted fragment size. The usefulness of the semi-quantitative RT-PCR has been described elsewhere. 19 ± 21 
Statistical methods
Results are given as the mean AE s.e.m. (standard error). Statistical differences and interactions were evaluated through a factorial two way analysis of variance (obesity, OÂTrecadrine, T). When statistically signi®cant differences resulted at the interaction level, a Student's t-test was carried out to compare the effects of each treatment. Pearson correlations and regression coef®cients were performed to verify the relationships between WAT O 2 consumption and muscle UCP2 mRNA expression. Differences were considered as statistically signi®cant at P`0.05.
Results
The experimental group, eating a cafeteria diet for 75 days, increased ®nal body weight signi®cantly ( 19%, P`0.001) as well as body weight gain ( 47%, P`0.01) when compared to lean control rats (Table 1) . Body fat content was also signi®cantly higher ( 132%, P`0.001) in the cafeteria-fed rats than in the control animals. However, Trecadrine administration for 35 days signi®cantly reduced total fat content (760%, P`0.001) in the cafeteria ± obese rats when compared to obese non-treated rats. Also, Trecadrine treatment for 35 days signi®cantly diminished fat deposition (740%, P`0.05) in lean treated Figure 1 Relationship between input of total RNA in the reaction and countsamm 2 of the ampli®cation band after RT-PCR of OB, UCP1 and UCP2 products in WAT, BAT and gastrocnemius muscle, respectively.
A novel b 3 -adrenergic agonist and obesity-related gene expression B Berraondo et al rats as compared to lean untreated rats. A statistically signi®cant interaction (P`0.001) between obesity and Trecadrine treatment on fat stores was found (Table 1) . Furthermore, energy intake was affected by cafeteria diet intake and Trecadrine administration (Table 1) . Absolute abdominal WAT weights were signi®-cantly increased ( 117%, P`0.001), in rats fed the cafeteria diet when compared to lean controls. Trecadrine administration for 35 days signi®cantly decreased WAT content when compared to obese and lean control non-treated rats, respectively (760%, P`0.001; 736%, P`0.05). The two-way analysis of variance indicated that obesity and Trecadrine treatment interacted on WAT weight (Table 1) . Furthermore, obesity and Trecadrine administration signi®cantly (P`0.001 and P`0.01, respectively) modi®ed BAT weight (Table 1) , while liver and muscle weights remained unchanged (data not shown).
After 75 days of feeding animals on a cafeteria diet, in vitro WAT O 2 consumption was signi®cantly higher ( 53%, P`0.01) in those rats developing the obesity model than in control rats (Table 1) . On the other hand, Trecadrine administration for 35 days, signi®cantly increased WAT O 2 consumption ( 34%, P`0.05) as compared to the obese non-treated rats. A statistically signi®cant interaction (P`0.05) was found between obesity and the effect of Trecadrine treatment on O 2 consumption in white adipose tissue (Table 1) .
Plasma leptin and fatty acids concentrations were higher ( 50%, P`0.05; 22%, n.s, respectively) in rats fed the cafeteria diet than in lean control (Table  2) . However, Trecadrine administration for 35 days to obese animals signi®cantly diminished leptin and fatty acid concentrations (776%, P`0.001; 736%, P`0.01, respectively) as compared to obese nontreated rats (Table 2 ). Leptin and fatty acid concentrations, after Trecadrine administration for 35 days, fell (759%, P`0.001; 742%, n.s, respectively) in lean control-treated rats as compared with lean untreated animals ( Table 2) . A statistically signi®cant interaction (P`0.05) between obesity and Trecadrine treatment on plasma leptin concentrations was found (Table 2) . Furthermore, a signi®cant decrease in plasma insulin was observed after Trecadrine administration (P`0.05), while plasma glucose remained unchanged, as shown by a two-way analysis of variance ( Table 2) .
As expected, WAT OB mRNA levels were signi®-cantly higher ( 210%, P`0.05 ) in obese cafeteriafed rats when compared to control lean rats. However, Trecadrine treatment signi®cantly reduced (768%, e P`0.001, obese vs obese T animals.
A novel b 3 -adrenergic agonist and obesity-related gene expression B Berraondo et al P`0.05) WAT OB mRNA levels as compared to non-treated obese rats. The two-way analysis of variance indicated that there was an interaction between obesity onset and Trecadrine treatment (P`0.05) in OB mRNA levels ( Figure 2) . Moreover, an increase in UCP1 mRNA levels following Trecadrine administration was found (P`0.05), as shown by a two-way analysis of variance (Figure 2 ). UCP2 mRNA levels were signi®cantly lower (745%, P`0.05) in dietinduced obese rats when compared with control lean rats, while Trecadrine treatment in obese rats signi®-cantly increased ( 71%, P`0.05) UCP2 levels as compared with non-treated obese rats. On the other hand, Trecadrine treatment signi®cantly diminished (745%, P`0.05) muscle UCP2 mRNA in lean control treated rats as compared with lean untreated rats. Likewise, a statistically signi®cant interaction (P`0.01) between obesity and Trecadrine treatment on UCP2 mRNA levels was found ( Figure 2 ). Also, WAT O 2 consumption and muscle UCP2 expression levels showed a negative correlation in lean animals (r 70.50, P`0.05), but not in the cafeteria fed groups ( Figure 3 ).
Discussion
Attempts to develop effective obesity treatments have included studies showing that b 3 -adrenoceptor agonists are ef®cient in reducing body weight and adipose tissue mass following acute treatment of OBaOB mice or dietary obese rodents. 3, 22 Since their discovery in the early 1980s, 23 b 3 -adrenergic receptors have been cloned in humans, mice and rats. 24 ± 26 Thus, b 3 -adrenoceptors are expressed in WAT, BAT, skeletal muscle, heart, brain, airway tissues and gastrointestinal tissues of rodents, while in humans the b 3 -adrenoceptor mRNA has been reported to occur at least in WAT, BAT, gallbladder and colon. 4 In this context, Trecadrine, a molecule with high af®nity for b 3 -adrenoceptors and with anti-diabetic properties, 15 has been tested for its effectiveness and mechanistic involvement in a dietary obesity model. Rats eating a cafeteria diet for 75 days increased body weight, total fat content and BAT and WAT weights. However, Trecadrine administration reduced BAT and WAT stores, in agreement with previous trials using other b 3 -adrenergic agonists such as BRL-35135, 27 CL316,243 28 and ICI D7114. 29 These events have been associated with an increase in WAT and BAT O 2 consumption and a reduction in the respiratory quotient, which was accompanied by a higher thermogenic activity in BAT and basal lipolysis in WAT. 8 Furthermore, an increase in food intake was found in Trecadrine-treated animals, which has been reported after BRL35135A administration 30 but not after CL 316243 treatment. 31 Figure 2 Effects of a cafeteria diet-induced obese model and Trecadrine administration (1 mgakg) for 35 days on OB, UCP1 and UCP2 mRNA levels in WAT, BAT and gastrocnemius muscle, respectively. Statistical analysis: two-way Anova (O, obesity; T, Trecadrine; OÂT, obesity plus Trecadrine) and Student's t-tests. *P`0.05, **P`0.01, signi®cant differences. n.s: non-signi®cant differences.
{ P`0.05, control vs control T animals.
{ P`0.05, control vs obese animals.
§ P`0.05, control T vs obese animals.
k P`0.05, obese vs obese T animals. Figure 3 Relationships between WAT O 2 consumption (ml O 2 amin g ml) and gastrocnemius muscle UCP2 mRNA levels (ratio UCP2ab-actin mRNA). A negative correlation between WAT O 2 consumption and muscle UCP2 mRNA expression (r 70.50, P`0.05) was found only for control groups.
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Trecadrine administration decreased plasma insulin concentrations in control and diet induced obese animals, which may be associated with the reduction in visceral fat and insulin resistance as well as a higher glucose utilization by tissues, as previously reported, 15 since plasma glucose and insulin concentrations followed a parallel trend.
The OB gene, 9 expressed at least in adipose tissue, 32 placenta, 33 and the stomach, 34 encodes a secreted protein which acts as an adipocyte-derived satiety factor regulating body weight homeostasis and energy expenditure. 35, 36 Our data show an association between WAT OB gene expression and plasma leptin levels (P 0.09), both being increased in cafeteria diet-induced obese rats as compared to lean animals fed a normal laboratory chow. Moreover, Trecadrine treatment produced a reduction in both OB gene expression and plasma leptin concentration in obesetreated rats, reaching similar values to those of lean controls. These results are in agreement with previous studies with other b 3 -adrenoceptor agonists. 12, 37, 38 The fact that a statistical interaction between the obesity status and b 3 -adrenergic administration has been found for the OB mRNA expression con®rms a speci®c inhibitory effect of this compound through a regulatory loop mediated by the sympathetic nervous system and b 3 adrenoceptors, 11, 12 although the reduction in fat mass in those obese animals treated with Trecadrine may also be involved. 39 BAT and skeletal muscle are sites of thermogenesis and lipid oxidation for heat generation or dissipation through UCP1, 2 and 3 activities. 13, 40, 41 These uncoupling proteins could play a role in mitochondrial oxidation, but also in the competition between lipid and carbohydrate utilization or even be involved in the lipid transport across membranes. Interesting differences have been found among these three UCPs in terms of both tissue distribution and physiological involvement. Thus, UCP1, which is expressed in BAT, appears to be particularly important in thermoregulation. 42, 43 As expected, an enhancement in BAT UCP1 mRNA levels by Trecadrine treatment was observed, as reported for other b 3 -adrenoceptor agonists such as CL 316243 and BRL 35135. 13, 44 The UCP2 occurring in WAT, BAT and other tissues 38 has been reported to be differently affected by dietary intake 13, 45, 46 as well as other physiological and nutritional circumstances. 47, 48 Thus, there are evidences about tissue-speci®c features concerning the adipose tissue and skeletal muscle in the mechanisms regulating UCP2 mRNA expression in response to fasting, refeeding or high fat intake. 46, 47, 49 In our experimental trial, rats eating a cafeteria diet showed a decrease in gastrocnemius muscle UCP2 expression as compared to control animals. These results are in agreement with the elevation of skeletal muscle UCP2 expression related to body weight losses induced by diet restriction and with the overexpression of muscle UCP2 in human obesity associated with reduced skeletal muscle lipid utilization, 50 which has been attributed to a compensatory mechanism as a defence against hypothermogenesis. 51 Furthermore, fasting or food deprivation conditions appear to produce an UCP2 up-regulation, while refeeding produces a down-regulation in muscle UCP2 mRNA expression. 47 The effects of b 3 -adrenergic agonists on UCP2 gene expression, which seems also to be tissue-dependent, have been reported inconsistently by investigators. Thus, an increase in WAT and BAT UCP2 gene expression after b 3 -adrenergic agonist administration has been found, 40, 49 while the UCP2 expression was strikingly decreased in skeletal muscle after adrenergic agonist administration in lean animals, 52 but not in Zucker rats. 53 In our study, control rats treated with Trecadrine had reduced muscle UCP2 expression, which could be related to changes in plasma insulin and free fatty acids (FFA), since it has been reported that the levels of insulin and FFA may be important regulators of the muscle UCP2 expression. 52 On the contrary, Trecadrine treatment enhanced gastrocnemius muscle UCP2 mRNA levels in obese animals. In this context, it is remarkable that cold, as well as T 3 administration appears to up-regulate UCP2 gene expression, 49 which was accompanied by lower body weights in the T 3 -treated animals. 54 Muscle UCP2 content have been found to be positively correlated with fat content. 50 In this context, a statistical negative relationship was obtained between UCP2 gene expression and oxygen consumption in white adipose tissue in lean animals, but not in obese rats. This observation gives further support to the hypothesis that muscle UCP2 may have different roles in thermogenesis when adipose tissue depots are being depleted by the b 3 -adrenergic agonist depending of the ponderal status. Thus, muscle UCP2 gene expression in control-treated animals is down-regulated, while in diet-induced obesity animals muscle UCP2 is up-regulated.
In conclusion, Trecadrine administration decreases fat content and modi®es OB, UCP1 and UCP2 gene expression in adipose tissues and gastrocnemius muscle in a cafeteria diet-induced obesity model, which may have some potential clinical applications, particularly by the fact that an up-regulation of muscle UCP2 mRNA levels has been found after b 3 -adrenergic agonist administration to obese rodents, but not in lean animals. Furthermore, the statistical interactions between cafeteria feeding and Trecadrine administration concerning fat content, WAT O 2 consumption and plasma leptin lends further support to a differential mechanism of action of b 3 -adrenergic agonist depending on the weight status.
